Having placed leaders into roles like this repeatedly, we wrote this to give a practitioner’s view rather than generic advice. Building a leadership team ahead of a MedTech IPO is a countdown, because public markets scrutinize device companies on regulatory credibility, clinical evidence, and commercial execution, and the team must be able to withstand that scrutiny. A pre-IPO MedTech company needs public-company-ready leadership in finance, regulatory, quality, and commercial, and building it takes far longer than most boards plan for.
Key Takeaways
- Public markets scrutinize MedTech on regulatory, clinical, and commercial credibility.
- A public-company-ready CFO is the most critical and time-consuming hire.
- Regulatory and quality leadership must withstand investor and auditor scrutiny.
- Start building the team well before the offering, not months out.
- The team must tell a credible story to public investors.
What Public Markets Demand of a MedTech Team
A MedTech IPO exposes the company to a specific kind of scrutiny: investors and analysts assess the credibility of the regulatory pathway, the strength of the clinical evidence, the quality systems behind the product, and the commercial execution plan, alongside the financials. The leadership team must be able to withstand and answer that scrutiny credibly. This means the pre-IPO team needs not just capable executives but ones who can operate in a public-company environment and speak credibly to sophisticated investors about regulatory, clinical, and commercial reality. Building that team is a prerequisite for a successful offering, not an afterthought to it.
The Critical Pre-IPO Roles
Certain roles matter disproportionately. The CFO is paramount: a MedTech company going public needs a CFO who can run public-company finance, reporting, controls, and investor relations, and who can articulate the company’s economics to investors, and a CFO without public-company or IPO experience is a serious gap. Regulatory and quality leadership also matter enormously, since investors and auditors probe the regulatory pathway and quality systems, and weak leadership there raises red flags. Commercial leadership must be credible on the path to revenue. Assess which of these roles are strong enough for public scrutiny and address gaps early.
Timing the Build
Building public-company-ready MedTech leadership takes time: senior hires take months to find and close, then months more to establish themselves and build the readiness a public company requires. A CFO hired shortly before an offering has no time to build the reporting and control infrastructure, and a regulatory or quality gap discovered late cannot be closed quickly. This is why the pre-IPO leadership build is a countdown that should start a year or more ahead. Boards that treat the IPO as primarily a financial event, and leave the leadership build late, create real risk to the offering and to the company’s post-IPO performance.
What This Looks Like in Practice
A MedTech company preparing to go public assesses its leadership against public-company scrutiny early, identifies gaps in finance, regulatory, quality, and commercial leadership, and hires well ahead of the offering so new leaders can establish themselves. It prioritizes a CFO with genuine public-company or IPO experience. It does not treat the IPO as a purely financial event, assume the private-company team will translate, or leave critical hires until months before the offering.
The Mistake Employers Keep Making
The most common mistake is leaving the leadership build until the IPO process is underway, then scrambling for a CFO or discovering a regulatory or quality leadership gap that investors and auditors will probe. Public-company readiness, especially in finance and in the regulatory and quality functions that MedTech investors scrutinize, takes time to establish. The company mistakes the IPO for a financing exercise rather than a leadership readiness test, and pays for it with a weaker offering or a difficult first year as a public company.
Pre-IPO MedTech Leadership Readiness
| Function | What Public Markets Scrutinize | When to Address |
|---|---|---|
| CFO / finance | Reporting, controls, investor relations | 12+ months ahead |
| Regulatory | Credibility of the pathway and strategy | Early |
| Quality | Quality systems and audit readiness | Early |
| Commercial | Credible path to revenue | Ahead of the process |
The Bottom Line
A pre-IPO MedTech company must build leadership that can withstand public-market scrutiny of its regulatory, clinical, commercial, and financial story, especially a public-company-ready CFO, and since that takes far longer than most boards plan, start the leadership countdown a year or more ahead rather than scrambling as the offering approaches. The employers who hire well here are the ones who respect what makes the role specific, and search accordingly.
Related Reading
For more, see Executive Search Strategies for MedTech Startups Scaling Post-Series B, What Boards Should Know Before a MedTech CEO Search, What to Look for in a Head of Quality Systems (MedTech).
Frequently Asked Questions
- Q: What do public markets scrutinize in a MedTech company?
- A: The credibility of the regulatory pathway, the strength of clinical evidence, the quality systems, and commercial execution, alongside the financials.
- Q: Which pre-IPO role matters most?
- A: The CFO; a MedTech company going public needs a CFO who can run public-company finance, reporting, controls, and investor relations and articulate the economics to investors.
- Q: Why do regulatory and quality leadership matter pre-IPO?
- A: Because investors and auditors probe the regulatory pathway and quality systems, so weak leadership in those functions raises red flags during the offering.
- Q: When should the pre-IPO leadership build start?
- A: A year or more ahead, since senior hires take months to close and months more to establish the public-company readiness the offering requires.
- Q: What is the common pre-IPO mistake?
- A: Leaving the leadership build until the IPO process is underway, then scrambling for a CFO or discovering regulatory or quality gaps that cannot be closed quickly.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
